IOBT IO Biotech, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market.
IOBT revenue and earnings
- Quarter ended Sep 30, 2025: revenue n/a, net income −$8.38M, EPS -0.13
- Quarter ended Jun 30, 2025: revenue n/a, net income −$26.2M, EPS -0.40
- Quarter ended Mar 31, 2025: revenue n/a, net income −$22.4M, EPS -0.34
- Quarter ended Dec 31, 2024: revenue n/a, net income −$31.3M, EPS -0.48
Recent IOBT insider trades
- May 30, 2025: Hunter Heidi bought 15,000 shares ($20.9K)
- Dec 23, 2024: Ahmad Qasim Iftikhar bought 31,350 shares ($26.6K)
- Dec 23, 2024: Zocca Mai-Britt bought 12,500 shares ($10.1K)
- Dec 23, 2024: Sullivan Amy bought 10,250 shares ($8.51K)
5%+ owners
- Lundbeckfond Invest A/S: 27.4% (Schedule 13D/A, filed Jun 2, 2026)
Are insiders buying or selling IOBT?
No open-market insider buys or sells of IO Biotech, Inc. were reported in the last 12 months.